Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America
CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America
CLNN
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea
058820
CNS Pharmaceuticals, Inc. Logo
Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.
United States of America
CNSP
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America
COCP
Co-Diagnostics, Inc. Logo
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America
CODX
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP

Talk to a Data Expert

Have a question? We'll get back to you promptly.